255 related articles for article (PubMed ID: 30622832)
1. Current therapies and novel approaches for biliary diseases.
Rajapaksha IG; Angus PW; Herath CB
World J Gastrointest Pathophysiol; 2019 Jan; 10(1):1-10. PubMed ID: 30622832
[TBL] [Abstract][Full Text] [Related]
2. Chronic cholestatic liver diseases: clues from histopathology for pathogenesis.
Pollheimer MJ; Fickert P; Stieger B
Mol Aspects Med; 2014 Jun; 37():35-56. PubMed ID: 24141039
[TBL] [Abstract][Full Text] [Related]
3. Activation of biliary tree stem cells within peribiliary glands in primary sclerosing cholangitis.
Carpino G; Cardinale V; Renzi A; Hov JR; Berloco PB; Rossi M; Karlsen TH; Alvaro D; Gaudio E
J Hepatol; 2015 Nov; 63(5):1220-8. PubMed ID: 26119688
[TBL] [Abstract][Full Text] [Related]
4. Liver-Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug-Resistant Gene 2-Knockout Mice.
Rajapaksha IG; Gunarathne LS; Asadi K; Cunningham SC; Sharland A; Alexander IE; Angus PW; Herath CB
Hepatol Commun; 2019 Dec; 3(12):1656-1673. PubMed ID: 31832573
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of biliary fibrosis.
Pinzani M; Luong TV
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1279-1283. PubMed ID: 28754450
[TBL] [Abstract][Full Text] [Related]
6. Cholestatic liver diseases: new targets, new therapies.
Santiago P; Scheinberg AR; Levy C
Therap Adv Gastroenterol; 2018; 11():1756284818787400. PubMed ID: 30159035
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiology and Diseases of the Proximal Pathways of the Biliary System.
Nakanishi Y; Saxena R
Arch Pathol Lab Med; 2015 Jul; 139(7):858-66. PubMed ID: 26125426
[TBL] [Abstract][Full Text] [Related]
8. Nuclear Translocation of RELB Is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice.
Elßner C; Goeppert B; Longerich T; Scherr AL; Stindt J; Nanduri LK; Rupp C; Kather JN; Schmitt N; Kautz N; Breuhahn K; Ismail L; Heide D; Hetzer J; García-Beccaria M; Hövelmeyer N; Waisman A; Urbanik T; Mueller S; Gdynia G; Banales JM; Roessler S; Schirmacher P; Jäger D; Schölch S; Keitel V; Heikenwalder M; Schulze-Bergkamen H; Köhler BC
Gastroenterology; 2019 Mar; 156(4):1190-1205.e14. PubMed ID: 30445013
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of intercellular adhesion molecule 1 on bile ducts in primary biliary cirrhosis and primary sclerosing cholangitis.
Adams DH; Hubscher SG; Shaw J; Johnson GD; Babbs C; Rothlein R; Neuberger JM
Hepatology; 1991 Sep; 14(3):426-31. PubMed ID: 1714872
[TBL] [Abstract][Full Text] [Related]
10. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
Hay JE
Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
[TBL] [Abstract][Full Text] [Related]
11. Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.
Fabris L; Fiorotto R; Spirli C; Cadamuro M; Mariotti V; Perugorria MJ; Banales JM; Strazzabosco M
Nat Rev Gastroenterol Hepatol; 2019 Aug; 16(8):497-511. PubMed ID: 31165788
[TBL] [Abstract][Full Text] [Related]
12. The Emerging Role of Macrophages in Chronic Cholangiopathies Featuring Biliary Fibrosis: An Attractive Therapeutic Target for Orphan Diseases.
Cadamuro M; Girardi N; Gores GJ; Strazzabosco M; Fabris L
Front Med (Lausanne); 2020; 7():115. PubMed ID: 32373615
[TBL] [Abstract][Full Text] [Related]
13. Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics.
Park JW; Kim JH; Kim SE; Jung JH; Jang MK; Park SH; Lee MS; Kim HS; Suk KT; Kim DJ
Biomedicines; 2022 May; 10(6):. PubMed ID: 35740310
[TBL] [Abstract][Full Text] [Related]
14. Recognizing primary biliary cirrhosis and primary sclerosing cholangitis.
Buckley SE; DiPalma JA
Am Fam Physician; 1996 Jan; 53(1):195-200. PubMed ID: 8546046
[TBL] [Abstract][Full Text] [Related]
15. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease.
Luketic VA; Sanyal AJ
Gastroenterologist; 1994 Mar; 2(1):74-9. PubMed ID: 8055235
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Review of Molecular Mechanisms during Cholestatic Liver Injury and Cholangiocarcinoma.
Virani S; Akers A; Stephenson K; Smith S; Kennedy L; Alpini G; Francis H
J Liver; 2018; 7(3):. PubMed ID: 30613437
[TBL] [Abstract][Full Text] [Related]
17. Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets.
Sato K; Glaser S; Kennedy L; Liangpunsakul S; Meng F; Francis H; Alpini G
Expert Opin Ther Targets; 2019 Jun; 23(6):461-472. PubMed ID: 30990740
[TBL] [Abstract][Full Text] [Related]
18. Relationship of pretransplant hepatobiliary disease to bile duct damage occurring in the liver allograft.
Fennell RH; Shikes RH; Vierling JM
Hepatology; 1983; 3(1):84-9. PubMed ID: 6295909
[TBL] [Abstract][Full Text] [Related]
19. The Cholangiopathies.
Lazaridis KN; LaRusso NF
Mayo Clin Proc; 2015 Jun; 90(6):791-800. PubMed ID: 25957621
[TBL] [Abstract][Full Text] [Related]
20. Vitamin A deficiency in chronic cholestatic liver disease: Is vitamin A therapy beneficial?
Freund C; Gotthardt DN
Liver Int; 2017 Dec; 37(12):1752-1758. PubMed ID: 28371374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
